Executive Summary

CONITEC advises the MoH regarding the reimbursement of new products. CONITEC is not able to assess all new drugs and therefore only assesses those which have been requested for a review by various stakeholders (such as manufacturers, patient associations and the MoH). The HTA evaluation takes into account he costs and benefits of a new product. An ICER of the product must be submitted, although there no set cost-effectiveness thresholds for decision making in place. Products can either be recommended, restricted or excluded/withdrawn from RENAME. Reimbursement of orphan drugs may be challenging as there are no orphan drug specific programs in place (e.g. early access, funding).